Tipu Faiz Saleem, MD
Endocrinology, Diabetes & Metabolism · Lititz, PANPI 1215934609
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $105,979 of the $118,445 with a category attached, or 89.5%. 27 manufacturers reported payments, led by Sanofi-aventis U.S. LLC at 55.6% of the total. Reporting peaked in 2019 at $54,973 and has fallen 97.1% since, to $1,568 in 2025. Among endocrinology, diabetes & metabolism clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 266 payments — averaging $445.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$66K
- AstraZeneca$28K
- Mannkind Corporation$19K
- Corcept Therapeutics$3K
- Amgen$1K
- Novo Nordisk$246
- plus $1K from 21 others
What the payments were for
- Consulting fees$3,1003%
- Speaking & faculty fees$105,97989%
- Travel & lodging$3,0593%
- Food & beverage$6,1995%
- Education$480%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 79 | $65,846 |
| AstraZeneca | 41 | $27,874 |
| Mannkind Corporation | 41 | $18,886 |
| Corcept Therapeutics | 8 | $3,198 |
| Amgen(2 entities) | 32 | $1,152 |
| Novo Nordisk | 9 | $246 |
| Lilly USA, LLC | 9 | $175 |
| BETA Bionics, Inc. | 3 | $132 |
| IBSA Pharma Inc. | 5 | $110 |
| Acella Pharmaceuticals, LLC | 5 | $96 |
| Tandem Diabetes Care, Inc. | 3 | $89 |
| Amneal Pharmaceuticals LLC | 4 | $82 |
| Bayer | 4 | $68 |
| Madrigal Pharmaceuticals | 2 | $67 |
| Ascendis Pharma Endocrinology Inc | 2 | $58 |
| Boehringer Ingelheim | 3 | $53 |
| Dexcom, Inc. | 2 | $47 |
| AbbVie | 2 | $42 |
| Neurocrine Biosciences, Inc. | 1 | $37 |
| Eisai Inc. | 3 | $36 |
| Xeris Pharmaceuticals, Inc. | 2 | $30 |
| Abbott | 1 | $30 |
| Antares Pharma, Inc. | 1 | $20 |
| Averitas Pharma Inc. | 1 | $20 |
| Radius Health, Inc. | 1 | $20 |
| Kyowa Kirin, Inc. | 1 | $16 |
| Sequel Med Tech, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOLIQUA 100/33$45,013
- FARXIGA$27,282
- TOUJEO$21,772
- AFREZZA$18,197
- Korlym$3,149
- TEPEZZA$381
- iLet Bionic Pancreas$320
- Prolia$250
- EVENITY$125
- iLet Insulin Infusion Kit Inset$107
- iLet Insulin Infusion Kit Contact Detach$107
- Saxenda$101
How this compares
$118,445 in reported general payments places this provider in the 90th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
See all endocrinology, diabetes & metabolism providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 305 | $387,354 |
| OzempicSemaglutide | 245 | $331,811 |
| FarxigaDapagliflozin Propanediol | 325 | $304,397 |
| TrulicityDulaglutide | 186 | $281,862 |
| JardianceEmpagliflozin | 266 | $245,968 |
| Tresiba Flextouch U-200Insulin Degludec | 98 | $166,483 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 71 | $103,758 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 59 | $98,590 |
| Tresiba Flextouch U-100Insulin Degludec | 105 | $76,765 |
| Novolog FlexpenInsulin Aspart | 215 | $66,122 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 46 | $62,944 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 76 | $53,833 |
| JanuviaSitagliptin Phosphate | 29 | $40,052 |
| InvokanaCanagliflozin | 30 | $32,227 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 41 | $31,239 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $175 | $676,921518 claims |
| Novo NordiskOzempic, Xultophy 100-3.6, Novolog | $246 | $375,366306 claims |
| AstraZenecaFarxiga | $27,874 | $304,397325 claims |
| Boehringer IngelheimJardiance, Tradjenta | $53 | $266,448297 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $65,846 | $103,75871 claims |
| AmgenProlia | $1,152 | $20,91612 claims |
| AbbVieSynthroid | $42 | $7,23599 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $82 | $5,733614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
Other endocrinology, diabetes & metabolism in Lititz
- Serge JabbourPhiladelphia$1.2M
- Vijay BahlPittsburgh$998K
- Geraldo SaavedraWhitehall$698K
- Jane MayrinPhiladelphia$628K
- Stephan KowalykGreensburg$591K
- Matthew KaneWest Chester$577K
- Intekhab AhmedPhiladelphia$528K
- Swarna VarmaPittsburgh$520K
- James DickeHanover$425K
- Mitchell LazarPhiladelphia$358K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.